American Well (NYSE:AMWL) Price Target Raised to $6.50 at Morgan Stanley

American Well (NYSE:AMWL) had its price target lifted by Morgan Stanley from $6.00 to $6.50 in a research note released on Wednesday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock.

A number of other brokerages have also recently issued reports on AMWL. Wall Street Zen upgraded American Well from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of American Well in a report on Wednesday, January 21st. Finally, Stifel Nicolaus lowered their price target on American Well from $6.00 to $5.00 and set a “hold” rating for the company in a research report on Friday, February 13th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.58.

American Well Stock Performance

Shares of AMWL opened at $7.14 on Wednesday. American Well has a fifty-two week low of $3.71 and a fifty-two week high of $9.15. The firm’s 50-day simple moving average is $5.72 and its two-hundred day simple moving average is $5.04. The stock has a market cap of $118.18 million, a PE ratio of -1.32 and a beta of 1.52.

American Well (NYSE:AMWL) last released its earnings results on Tuesday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.11. American Well had a negative net margin of 37.02% and a negative return on equity of 31.22%. The firm had revenue of $54.88 million during the quarter, compared to analyst estimates of $51.54 million. Equities research analysts predict that American Well will post -2.88 EPS for the current year.

Insiders Place Their Bets

In related news, insider Dmitry Zamansky sold 5,575 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $5.30, for a total value of $29,547.50. Following the completion of the transaction, the insider directly owned 241,080 shares in the company, valued at $1,277,724. The trade was a 2.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 9,664 shares of company stock valued at $51,219. 11.82% of the stock is owned by insiders.

Institutional Trading of American Well

Institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. lifted its holdings in shares of American Well by 280.6% during the first quarter. Goldman Sachs Group Inc. now owns 64,760 shares of the company’s stock valued at $510,000 after purchasing an additional 47,745 shares in the last quarter. Jane Street Group LLC boosted its position in shares of American Well by 232.9% during the first quarter. Jane Street Group LLC now owns 64,112 shares of the company’s stock valued at $505,000 after buying an additional 44,852 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in American Well by 16.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 14,720 shares of the company’s stock worth $131,000 after buying an additional 2,081 shares in the last quarter. Norges Bank bought a new stake in American Well in the 2nd quarter worth about $250,000. Finally, Engineers Gate Manager LP purchased a new position in American Well in the 2nd quarter worth about $101,000. Institutional investors own 56.05% of the company’s stock.

Trending Headlines about American Well

Here are the key news stories impacting American Well this week:

• Positive Sentiment: Q1 results: AMWL reported revenue of $54.9M and GAAP EPS that topped consensus (company reported ($0.66) EPS and revenue above estimates), showing sequential improvement vs. last year — this beat is a near-term positive catalyst for the stock. Amwell Press Release
• Positive Sentiment: TD Cowen raised its price target from $5 to $8 and kept a “hold” rating — the higher PT supports upside expectations and likely helped buying interest. Benzinga
• Neutral Sentiment: Guidance: Amwell issued Q2 revenue guidance of $48M–$52M and FY26 revenue guidance of $195M–$205M, roughly in line with Street estimates (midpoints near consensus) — this reduces surprise risk but doesn’t represent a clear beat. Amwell Press Release
• Neutral Sentiment: Earnings call transcript is available for investors who want detail on cadence, customer wins, margin drivers and visibility — useful for assessing durability of the beat. Seeking Alpha Transcript
• Negative Sentiment: Morgan Stanley raised its target slightly to $6.50 but maintains an “equal weight” rating; that PT implies roughly a mid-single-digit downside vs. the current price, signaling some analysts still see limited near-term upside. TickerReport / Benzinga
• Negative Sentiment: Alternate reporting (Zacks) showed a marginal EPS miss (-$0.78 vs. est. -$0.77), highlighting that EPS comparisons are close and some data providers flag small shortfalls — a reminder of volatility in quarterly metrics. Zacks

About American Well

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.